Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
The said inspection concluded with Zero Form 483 observation
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
US business grew by +12.8% YoY
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
